1. Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy 
Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási, MD, Beáta Visy, MD, György Harmat, MD, PhD, George Füst, MD, PhD, DSc, Gábor Széplaki, MD, Béla Fekete, MD, PhD, DSc, István Karádi, MD, PhD, DSc, Lilian Varga, PhD 
Journal of Allergy and Clinical Immunology 
Volume 120, Issue 4, Pages (October 2007)
DOI: /j.jaci
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Number of ampoules of hC1-INH concentrate used for the treatment of the patients with HAE during follow-up. A, Number of ampoules received over the lifetime of a patient. B, Average number of ampoules per year (corrected for the duration of follow-up).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Time to relief and complete resolution of symptoms after treatment with hC1-INH concentrate. Laryngeal edema responded most rapidly to the treatment and the time for complete resolutions was the shortest compared with gastrointestinal and subcutaneous edema. Both time to relief and complete resolution of symptoms were longest in patients with subcutaneous edema. P values were calculated with the χ2 for trend.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Changes of anti–C1-INH autoantibody titers during follow-up. No significant increase or decrease was observed in anti-C1-INH titers during the follow-up of patients with HAE who ever received hC1-INH concentrate. Lines indicate medians and 25th to 75th percentiles. P values were calculated with the Wilcoxon signed-rank test.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions